Patents by Inventor Eric A. Kemp

Eric A. Kemp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS
    Publication number: 20240218009
    Abstract: Novel forms of 2-amino-9-[(2R,5R,7R,8S,10R,12aR, 14R,15S,15aR,16R)-14-(6-amino-9H-purin-9-yl)-15,16-difluoro-2,10-dihydroxy-2,10-disulfidooctahydro-12H-5,8-methanofuro[3,2-1][1,3,6,9,11,2,10]pentaoxadiphospha-cyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one, which include adducts of 2-amino-9-[(2R,5R,7R,8S,10R,12aR, 14R,15S,15aR,16R)-14-(6-amino-9H-purin-9-yl)-15,16-difluoro-2,10-dihydroxy-2,10-disulfidooctahydro-12H-5,8-methanofuro[3,2-1][1,3,6,9,11,2,10]pentaoxadiphospha-cyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one and L-histidine, may be useful as inductors of type I interferon production, specifically as STING active agents.
    Type: Application
    Filed: April 18, 2022
    Publication date: July 4, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Stephanus Axnanda, Andrew Patrick Jude Brunskill, Erin N. Guidry, Eric A. Kemp, Courtney K. Maguire, Mikhail Reibarkh, Matthew S. Winston
  • MINI-TABLET DOSAGE FORM OF A VIRAL TERMINASE INHIBITOR AND USES THEREOF
    Publication number: 20240041882
    Abstract: The present invention relates to oral dosage forms comprising letermovir and, in particular, to compressed mini-tablets comprising letermovir. The invention also relates to methods of using the oral dosage forms for the treatment, prevention, or prophylaxis of HCMV in a patient. In addition, the invention also provides methods for making the mini-tablets of the invention.
    Type: Application
    Filed: December 14, 2021
    Publication date: February 8, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Cory Bottone, Andrew J. Gmitter, Ashley R. Johnson, Eric A. Kemp, Feng Li, Fochive Njikam, Michael H. Wang
  • STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20220175811
    Abstract: The invention relates to stable formulations of cyclic dinucleotide STING agonist compounds or pharmaceutically acceptable salts thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intratumoral or subcutaneous administration.
    Type: Application
    Filed: March 24, 2020
    Publication date: June 9, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Margaret Brunell, Erin N. Guidry, Yash Kapoor, Eric A. Kemp, Ellen C. Minnihan, Sachin Mittal, Elizabeth Pierson, Mikhail Reibarkh, Tammy W. Shen, Erika R. Walsh, Paul L. Walsh